InterMune's ASCENDancy

InterMune Inc. (NASDAQ:ITMN) was rewarded by investors last week after detailed Phase III IPF data suggested its Esbriet pirfenidone may have the upper hand against nintedanib from Boehringer Ingelheim GmbH.